Chevy Chase Trust Holdings LLC Sells 60,685 Shares of Illumina, Inc. $ILMN

Chevy Chase Trust Holdings LLC lowered its stake in shares of Illumina, Inc. (NASDAQ:ILMN) by 11.5% in the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 464,979 shares of the life sciences company’s stock after selling 60,685 shares during the quarter. Chevy Chase Trust Holdings LLC’s holdings in Illumina were worth $44,364,000 at the end of the most recent quarter.

Other large investors have also recently added to or reduced their stakes in the company. Diversified Trust Co bought a new stake in Illumina during the first quarter worth approximately $355,000. Bourgeon Capital Management LLC boosted its position in Illumina by 76.4% during the second quarter. Bourgeon Capital Management LLC now owns 141,896 shares of the life sciences company’s stock worth $13,538,000 after purchasing an additional 61,468 shares during the period. GC Wealth Management RIA LLC bought a new stake in Illumina during the second quarter worth approximately $2,289,000. State of Alaska Department of Revenue boosted its position in Illumina by 2.5% during the first quarter. State of Alaska Department of Revenue now owns 18,527 shares of the life sciences company’s stock worth $1,469,000 after purchasing an additional 445 shares during the period. Finally, waypoint wealth counsel bought a new stake in Illumina during the second quarter worth approximately $321,000. Institutional investors own 89.42% of the company’s stock.

Illumina Stock Performance

Shares of NASDAQ ILMN opened at $95.46 on Friday. The business has a fifty day simple moving average of $98.12 and a 200 day simple moving average of $90.68. The company has a current ratio of 1.81, a quick ratio of 1.41 and a debt-to-equity ratio of 0.66. The firm has a market capitalization of $14.67 billion, a price-to-earnings ratio of 12.08, a PEG ratio of 2.32 and a beta of 1.40. Illumina, Inc. has a one year low of $68.70 and a one year high of $156.66.

Illumina (NASDAQ:ILMN) last issued its earnings results on Thursday, July 31st. The life sciences company reported $1.19 EPS for the quarter, beating analysts’ consensus estimates of $1.02 by $0.17. The business had revenue of $1.06 billion during the quarter, compared to analyst estimates of $1.12 billion. Illumina had a return on equity of 28.93% and a net margin of 29.36%.Illumina’s revenue was down 4.8% on a year-over-year basis. During the same period in the prior year, the company posted $0.36 earnings per share. Illumina has set its FY 2025 guidance at 4.450-4.55 EPS. Sell-side analysts expect that Illumina, Inc. will post 4.51 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of research analysts have recently commented on the company. Scotiabank lowered Illumina from a “sector outperform” rating to a “sector perform” rating and set a $125.00 price target for the company. in a report on Friday, July 11th. Robert W. Baird upped their price target on Illumina from $84.00 to $105.00 and gave the stock a “neutral” rating in a report on Monday, July 28th. Evercore ISI cut their price target on Illumina from $135.00 to $132.00 and set an “outperform” rating for the company in a report on Tuesday, October 7th. Weiss Ratings reiterated a “sell (d+)” rating on shares of Illumina in a report on Wednesday, October 8th. Finally, Morgan Stanley upped their price target on Illumina from $100.00 to $105.00 and gave the stock an “equal weight” rating in a report on Monday, August 4th. Five investment analysts have rated the stock with a Buy rating, eleven have given a Hold rating and three have issued a Sell rating to the company’s stock. According to data from MarketBeat, Illumina has an average rating of “Hold” and a consensus target price of $115.25.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.